Excluded medication and dose-controlled medication

Ching Lam; Wei Tan; Matthew Leighton; Margaret Hastings; Melanie Lingaya; Yirga Falcone; Xiaoying Zhou; Luting Xu; Peter Whorwell; Andrew F Walls; Abed Zaitoun; Alan Montgomery; Robin C Spiller

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Lam C, Tan W, Leighton M, et al. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial. Southampton (UK): NIHR Journals Library; 2015 Mar. (Efficacy and Mechanism Evaluation, No. 2.2.)

Cover of Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial.

Show details

Contents

< Prev Next >

Appendix 1Excluded medication and dose-controlled medication

Please use in conjunction with the exclusion criteria definition.

Excluded medication

Non-steroidal anti-inflammatory drugs

Aceclofenac.

Acemetacin.

Aspirin.

Azapropazone.

Celecoxib.

Dexibuprofen.

Dexketoprofen.

Diclofenac sodium.

Etodolac.

Etoricoxib.

Fenbufen.

Fenoprofen.

Flurbiprofen.

Ibuprofen.

Indomethacin.

Ketoprofen.

Mefenamic acid.

Meloxicam.

Nabumetone.

Naproxen.

Piroxicam.

Sulindac.

Tenoxicam.

Tiaprofenic acid.

Long-term antibiotic drugs

Please refer to the latest version of the British National Formulary.

Antispasmodic drugs

Alverine citrate.

Mebeverine hydrochloride.

Peppermint oil.

Antimuscarinic drugs

Atropine sulphate.

Dicycloverine hydrochloride.

Hyoscine butylbromide.

Propantheline bromide.

Opiates/antidiarrhoeal drugs

Codeine.

Loperamide.

Morphine.

Anti-inflammatory drugs

Prednisolone.

Budesonide.

Hydrocortisone.

Azathioprine.

Mercaptopurine.

5-aminosalicylic acid-containing medication

Balsalazide disodium.

Mesalazine.

Olsalazine sodium.

Sulfasalazine.

Dose-controlled medication

Selective serotonin reuptake inhibitors

Citalopram.

Escitalopram.

Fluoxetine.

Fluvoxamine maleate.

Paroxetine.

Sertraline.

Tricyclic antidepressant drugs

Amitriptyline hydrochloride.

Clomipramine hydrochloride.

Dosulepin hydrochloride.

Doxepin.

Imipramine hydrochloride.

Lofepramine.

Nortriptyline.

Trimipramine.

Copyright © Queen’s Printer and Controller of HMSO 2015. This work was produced by Lam et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK280100

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Lam C, Tan W, Leighton M, et al. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial. Southampton (UK): NIHR Journals Library; 2015 Mar. (Efficacy and Mechanism Evaluation, No. 2.2.) Appendix 1, Excluded medication and dose-controlled medication.
PDF version of this title (4.8M)

Excluded medication and dose-controlled medication - Efficacy and mode of action...
Excluded medication and dose-controlled medication - Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf